NYSE:AEON
AEON Biopharma, Inc.
AEON Biopharma, Inc. reported net income of −$39.2M in fiscal 2025. Free cash flow was −$17.3M, and the diluted share count rose 1622.7%.Summary generated from AEON Biopharma, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$17.3M
FCF marginn/a
Share count change+1622.7%
Financials
| Item | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | −2 | −48 | 73 | −13 |
| Net income | 8 | −53 | 42 | −39 |
| Free cash flow | n/a | −36 | n/a | −17 |
Recent filings
- 8-KRegulation FD disclosure
Sep 30, 2026 - 4Insider transaction report
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KRegulation FD disclosure
Aug 3, 2026 - 8-KOther events
Jul 23, 2026 - 8-KEntry into a material agreement
Jul 15, 2026 - S-1Registration statement
Jul 8, 2026